Keywords
Leukemia, Myeloid, Acute ×
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

120 Search results.

Eligibility Leukemia, Myeloid NCT00512083

- 1/10/18 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00512083

Eligibility Leukemia, Myeloid NCT00611247

- 3/7/17 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00611247

Eligibility Leukemia, Myeloid NCT00512083

- 3/21/18 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00512083

Eligibility Leukemia, Myeloid NCT00512083

- 1/10/18 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia; Eligibility ODM derived from: https://clinicaltrials.gov/show/NCT00512083

Eligibility Leukemia, Myeloid New Model StudyXYZ - Eligibility Leukemia, Myeloid NCT00512083

- 1/10/18 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Description Study Eligibility Leukemia, Myeloid New Model StudyXYZ

Eligibility Philadelphia Positive Acute Lymphoblastic Leukemia NCT00199186

- 7/31/17 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL); ODM derived from: https://clinicaltrials.gov/show/NCT00199186

Eligibility Myelogenous Leukemia, Acute NCT00374296

- 5/15/17 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00374296

Eligibility Myelogenous Leukemia, Acute NCT00130702

- 5/15/17 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00130702

Eligibility Myeloblastic Leukemia NCT00799799

- 5/14/17 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells; ODM derived from: https://clinicaltrials.gov/show/NCT00799799

Eligibility Leukemia NCT00075010

- 10/4/16 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes; ODM derived from: https://clinicaltrials.gov/show/NCT00075010

Eligibility Advanced Cancers NCT01653717

- 9/10/16 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT01653717

Eligibility Leukemia NCT00022126

- 7/23/16 - 1 form, 1 itemgroup, 31 items, 1 language
Itemgroup: Criteria
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00022126